(Q33364235)

26 July 2017

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma (English)

1 reference

26 July 2017

0 references

1 reference

Schütt P

1

1 reference

26 July 2017

Ebeling P

2

1 reference

26 July 2017

Buttkereit U

3

1 reference

26 July 2017

Brandhorst D

4

1 reference

26 July 2017

Opalka B

5

1 reference

26 July 2017

Hoiczyk M

6

1 reference

26 July 2017

Flasshove M

7

1 reference

26 July 2017

Hense J

8

1 reference

26 July 2017

Bojko P

9

1 reference

26 July 2017

Metz K

10

1 reference

26 July 2017

Moritz T

11

1 reference

26 July 2017

Seeber S

12

1 reference

26 July 2017

Nowrousian MR

13

1 reference

26 July 2017

language of work or name

1 reference

1 January 2005

1 reference

European Journal of Haematology

26 July 2017

1 reference

26 July 2017

74

1 reference

26 July 2017

40-46

1 reference

26 July 2017

1

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

VAD chemotherapy as remission induction for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Thalidomide as initial therapy for early-stage myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00349.X

10.1111/J.1600-0609.2004.00349.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference